Stapp Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Stapp Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,643	Closed	-$236K	–	33
2025 Q3	$236K	Buy	+3,643	New	+$209K	0.32%	28
2024 Q2	–	Sell	-3,453	Closed	-$235K	–	23
2024 Q1	$235K	Buy	3,453 +3	+0.1%	+$215	0.41%	19
2023 Q4	$216K	Buy	+3,450	New	+$191K	0.36%	22
2022 Q4	–	Sell	-2,776	Closed	-$181K	–	38
2022 Q3	$181K	Buy	+2,776	New	+$201K	0.53%	18

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

GSK plc London $599M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stapp Wealth Management's CRSP Position: Q4 2025 in Review

Stapp Wealth Management sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 3,643 shares — an estimated $236K sold.

Stapp Wealth Management first reported a position in CRSP in Q3 2022 and held it in 4 quarters. The position peaked at $236K in Q3 2025. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

Stapp Wealth Management reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
Stapp Wealth Management sold 3,643 CRISPR Therapeutics shares in Q4 2025, an estimated $236K.
Stapp Wealth Management first reported a position in CRISPR Therapeutics in Q3 2022 and held it in 4 quarters.
Stapp Wealth Management's CRISPR Therapeutics position peaked at $236K in Q3 2025.
479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Stapp Wealth Management's 13F filing for Q4 2025, filed 21 Jan 2026.